Federal Filings LLC joined the leadership of Vogenx, Inc. at the Nasdaq MarketSite in Times Square on August 14, 2026. The Austin-based SEC EDGAR filing agent represented the clinical-stage biopharmaceutical company as it rang the opening bell to mark its $81.3 million initial public offering.

Managing Director Elliot Goldstein attended the ceremony on behalf of Federal Filings. The firm served as Vogenx’s EDGAR filing agent throughout the registration process and continues in that role for the company’s ongoing reporting obligations. This arrangement reflects the firm’s core business model: guiding an issuer through the offering phase and remaining for subsequent periodic filings, including 10-Qs, 10-Ks, 8-Ks, and inline XBRL (iXBRL) submissions.

Service Model and Operational Scope

Federal Filings handles EDGAR HTML conversion, inline XBRL tagging, and submission in-house. The firm provides marked proofs and Word proofs to ensure counsel’s working draft aligns with the filed document. It offers 24/7/365 coverage with a named production contact for every engagement.

The firm files for public companies, law firms, and institutional investors across various transaction types. These include IPOs, SPAC offerings, deSPAC mergers, reverse mergers, follow-on and resale registrations, foreign private issuer filings, and fund and ETF filings.

Cost Efficiency and Validation

Goldstein highlighted the firm’s proprietary conversion platform and automated iXBRL validation tools. He stated that these technologies have reduced costs in the filing process, challenging the notion that going public requires a legacy financial printer and a six-figure production budget.

"The bell is the fun part, but the work happens months before, usually at two in the morning, when a comment letter comes back and the registration statement has to be back on EDGAR clean before the market opens," Goldstein said. "Standing at the MarketSite with that team meant we got that part right."

What the Numbers Show

The $81.3 million IPO size for Vogenx indicates a modest capital raise for a clinical-stage biopharma entity. Federal Filings’ retention for ongoing reporting obligations suggests a long-term service contract beyond the initial listing event.